BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

The Native Antigen Company Ltd Releases Dengue Virus Serotype 2 NS1 Protein


6/20/2013 8:53:27 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

May 2013. The Native Antigen Company (NAC), http://www.thenativeantigencompany.com announces the release of its Dengue Virus serotype 2 NS1 protein (DENV2 NS1).

NAC’s DENV2 NS1 has been manufactured in response to the unmet need for a highly purified, concentrated protein for use in vaccine development and serological based diagnostic assays. To achieve this, the company has employed its novel VirTuETM platform which is based entirely on human cell lines using state-of-the-art expression techniques. The resultant DENV2 NS1 proteins are purified to a high degree, are in their native folding state, and possess all post-translational modifications. This advanced approach offers a product which delivers optimal antigenicity.

With more than one-third of the world’s population living in areas at risk of transmission, dengue infection is a leading cause of illness and death in the tropics and subtropics. As many as 100 million people are infected yearly. Dengue is caused by any one of four related viruses transmitted by mosquitoes. There are not yet any vaccines to prevent infection with dengue virus.

NAC is currently developing DENV1, DENV3 and DENV4 to cover the full spectrum of serotypes

For more information please contact Andrew Maxwell, CEO Native Antigen Company +44 (0) 1869 238067, amaxwell@thenativeantigencompany.com

or visit www.thenativeantigencompany.com

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES